Heat shock protein 90 targeting therapy: state of the art and future perspective.
Open Access
- 6 January 2015
- journal article
- review article
- Vol. 14, 48-58
- https://doi.org/10.17179/excli2014-586
Abstract
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that plays a role in stabilizing and activating more than 200 client proteins. It is required for the stability and function of numerous oncogenic signaling proteins that determine the hallmarks of cancer. Since the initial discovery of the first Hsp90 inhibitor in the 1970s, multiple phase II and III clinical trials of several Hsp90 inhibitors have been undertaken. This review provides an overview of the current status on clinical trials of Hsp90 inhibitors and future perspectives on novel anticancer strategies using Hsp90 inhibitors.Keywords
This publication has 50 references indexed in Scilit:
- A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancerBreast Cancer Research and Treatment, 2013
- Selective bladder preservation with curative intent for muscle‐invasive bladder cancer: A contemporary reviewInternational Journal of Urology, 2012
- A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerBreast Cancer Research and Treatment, 2011
- ErbB2 and NFκB Overexpression as Predictors of Chemoradiation Resistance and Putative Targets to Overcome Resistance in Muscle-Invasive Bladder CancerPLOS ONE, 2011
- A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid TumorsClinical Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaInvestigational New Drugs, 2010
- Impact of heat-shock protein 90 on cancer metastasisFuture Oncology, 2009
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- The Hallmarks of CancerCell, 2000